Almotriptan

證據等級: L5

預測適應症: 3 個

Almotriptan: From Migraine to Migraine with Brainstem Aura

One-Sentence Summary

Almotriptan is a selective serotonin 5-HT1B/1D receptor agonist belonging to the triptan class, established internationally for the acute treatment of migraine with or without aura, though it does not currently hold an MHRA marketing authorisation in the United Kingdom. The TxGNN model predicts it may be effective for Migraine with Brainstem Aura, with 0 registered clinical trials and 19 publications currently identified — though the available literature addresses general migraine rather than this specific subtype, and a notable safety concern applies to this predicted indication.

Quick Overview

Item	Content
Original Indication	Acute treatment of migraine with or without aura (FDA-approved internationally; no current UK MHRA authorisation)
Predicted New Indication	Migraine with Brainstem Aura
TxGNN Prediction Score	99.98%
Evidence Level	L3
UK Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Almotriptan belongs to the triptan class and acts as a selective agonist at serotonin 5-HT1B and 5-HT1D receptors. Detailed mechanism of action data are not available in this evidence pack; however, extensive published literature confirms that almotriptan exerts its antimigraine effect by causing selective vasoconstriction of dilated intracranial blood vessels and inhibiting the release of vasoactive neuropeptides — most notably calcitonin gene-related peptide (CGRP) and substance P — from peripheral trigeminal nerve terminals. These are the same core trigeminovascular targets implicated across all migraine subtypes.

Migraine with brainstem aura (formerly termed basilar-type migraine) is a distinct migraine subtype in which aura symptoms originate specifically from the brainstem or bilateral cortex, manifesting as dysarthria, vertigo, tinnitus, hypacusis, diplopia, ataxia, or decreased level of consciousness. Because it shares the same fundamental trigeminovascular pathophysiology as common migraine, the mechanistic rationale for triptan therapy is, in principle, preserved. Almotriptan’s well-documented efficacy across migraine with and without aura lends biological plausibility to its potential utility here.

However, the prediction carries an important safety caveat that limits straightforward translation to clinical practice. Triptans were historically listed as absolutely contraindicated in basilar and hemiplegic migraine, owing to theoretical concerns about basilar artery vasospasm and consequent brainstem or cerebellar ischaemia. More recent guidance from the International Headache Society (IHS) and national headache organisations has revised this to a relative contraindication, acknowledging that the evidence base for actual harm is sparse and largely theoretical. No dedicated randomised controlled trials have been conducted in patients with migraine with brainstem aura, meaning the risk–benefit profile for this specific subtype remains incompletely characterised.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
25600718	2015	Systematic Review / Guideline	Headache	American Headache Society updated evidence assessment of acute migraine pharmacotherapies; almotriptan established as an effective first-line acute treatment based on multiple RCTs
12455302	2002	RCT	Am J Health-Syst Pharm	Comprehensive review of pharmacology and clinical efficacy; confirms selective 5-HT1B/1D agonism and FDA-approved labelling for migraine with or without aura in adults
18302700	2008	RCT	Headache	AEGIS Trial: early almotriptan intervention significantly reduces migraine-associated functional disability versus placebo; supports prompt treatment of attacks
11768838	2001	RCT	Clinical Therapeutics	Randomised double-blind dose-finding study of subcutaneous almotriptan; efficacy and tolerability confirmed across dose range
30845850	2019	Narrative Review	Expert Rev Neurotherapeutics	20-year clinical review covering >15,000 patients and an estimated >150 million treated attacks; favourable long-term efficacy and tolerability profile confirmed
20945537	2010	Narrative Review	Expert Rev Neurotherapeutics	10-year review of RCTs and post-marketing studies; supports early intervention and broad applicability across migraine subtypes
25916333	2015	Comparative Review	J Headache Pain	Meta-analysis comparing frovatriptan versus almotriptan and other triptans for migraine with aura; demonstrates that triptans taken during the headache phase remain efficacious even in aura-associated attacks
27910087	2017	Review	Headache	Review of treatment options for menstrual migraine; almotriptan highlighted as an effective option for difficult-to-treat migraine subtypes with prolonged or severe attacks
12749502	2003	Review	Clinical Therapeutics	Argues for composite sustained pain-free rate as the most clinically meaningful endpoint; almotriptan demonstrates a favourable sustained response profile versus comparators
11380642	2001	Clinical Safety Study	Headache	Summary of pre-marketing safety and tolerability data; almotriptan exhibits a favourable cardiovascular safety profile relative to earlier-generation triptans

UK Market Information

Almotriptan currently holds no MHRA marketing authorisations in the United Kingdom and is not commercially available as a licensed medicine on the UK market.

For context, almotriptan is licensed in the United States under the brand name Axert® and has been available in several EU member states under the brand name Almogran® for the acute treatment of migraine with or without aura in adults. Any use in the UK would constitute use of an unlicensed medicine, subject to applicable MHRA guidance and prescriber responsibility.

Safety Considerations

Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.

Important safety note specific to this predicted indication: Triptans, including almotriptan, have historically been considered contraindicated in migraine with brainstem aura (formerly basilar-type migraine) due to theoretical risk of provoking basilar artery vasospasm and aggravating brainstem ischaemia. Current IHS guidance classifies this as a relative rather than absolute contraindication; however, no randomised trial data exist specifically for this subtype. Specialist neurology input should be obtained before any consideration of triptan use in patients with confirmed migraine with brainstem aura.

Conclusion and Next Steps

Decision: Hold

Rationale: Although almotriptan’s 5-HT1B/1D mechanism is biologically plausible for migraine with brainstem aura — given the shared trigeminovascular pathophysiology — the persistent safety concern around triptan-induced basilar vasospasm in this subtype, the complete absence of dedicated clinical trials, and the lack of any UK marketing authorisation collectively mean that a positive repurposing recommendation cannot be supported at this stage.

To proceed, the following is needed:

Prospective observational or controlled studies evaluating triptan safety and efficacy specifically in patients with confirmed migraine with brainstem aura (not general migraine populations)
Formal pharmacovigilance review of triptan exposure in brainstem aura cases using existing adverse event databases (MHRA Yellow Card, WHO VigiBase, FDA FAERS) to quantify real-world harm signal
Detailed mechanism of action data clarifying whether almotriptan’s vasoconstrictor effect differentially impacts the basilar versus other intracranial arterial territories
Specialist consensus statement from BASH (British Association for the Study of Headache) or equivalent body confirming the current status of triptans in brainstem aura
Should a positive evidence base emerge, a formal MHRA marketing authorisation application or named patient/specials route would be required before UK clinical use
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.